BLU-554
BLU-554 (Fisogatinib, BLU554) is a novel potent, highly selective and orally bioavailable inhibitor of FGFR4 designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation; targets FGFR4 while sparing other members of the FGFR family and showing little to no inhibition of all other kinases.Liver Cancer Phase 1 Clinical (In Vivo) :Tissue distribution of Fisogatinib (10 mg/kg; oral gavage; for 4 hours; FVB/NRj mice) in wild-type mice is as follows; tissue concentrations decreases in the order liver > kidney > small intestine > spleen > brain. The high Fisogatinib liver-to-plasma ratio suggests there is a relatively high amount of the drug being transported into the liver.
Product Specifications
CAS Number
1707289-21-1
Product Name Alternative
Fisogatinib | BLU554
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 25 mg/mL
Smiles
COC1=CC (=C (C (=C1Cl) C2=CC3=CN=C (N=C3C=C2) NC4COCCC4NC (=O) C=C) Cl) OC
Molecular Formula
C24H24Cl2N4O4
Molecular Weight
503.3777
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2-Propenamide, N-[ (3S,4S) -3-[[6- (2,6-dichloro-3,5-dimethoxyphenyl) -2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
SERPINB1 (Serpin Peptidase Inhibitor, Clade B (ovalbumin), Member 1, EI, ELANH2, LEI, M/NEI, MNEI, PI2) (PE)
Recombinant Staphylococcus saprophyticus subsp. saprophyticus Ribosome-binding factor A (rbfA)